Pheochromocytoma

Global Pheochromocytoma Market to Reach US$2.4 Billion by 2030

The global market for Pheochromocytoma estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2024-2030. Online Channel, one of the segments analyzed in the report, is expected to record a 1.3% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Offline Channel segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$587.3 Million While China is Forecast to Grow at 3.5% CAGR

The Pheochromocytoma market in the U.S. is estimated at US$587.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$444.2 Million by the year 2030 trailing a CAGR of 3.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Pheochromocytoma Market – Key Trends & Drivers Summarized

Why Is Early Diagnosis and Targeted Treatment of Pheochromocytoma Gaining Clinical Significance?

Pheochromocytoma, a rare neuroendocrine tumor arising from the adrenal medulla, is drawing increased attention in endocrinology and oncology due to its complex diagnosis, potential malignancy, and systemic implications. Although considered rare—with incidence rates estimated at 2 to 8 cases per million annually—pheochromocytoma presents significant health risks, including hypertensive crises, cardiac arrhythmias, and sudden death if undetected. These tumors secrete excess catecholamines such as adrenaline and noradrenaline, leading to episodic or persistent hypertension, palpitations, and metabolic disturbances.

Rising awareness among clinicians and improved availability of biochemical screening (plasma-free metanephrines, 24-hour urine catecholamines) are enhancing early detection rates. Genetic screening is also contributing to early identification, especially in patients with hereditary syndromes like MEN2, VHL, and NF1. As diagnostic tools become more sensitive and specific, early-stage detection is allowing for more effective surgical and pharmacological management—thus improving outcomes and reducing recurrence risks.

How Are Imaging Advances, Surgical Innovations, and Targeted Therapies Redefining Treatment Approaches?

Advancements in diagnostic imaging—such as CT, MRI, and functional imaging using MIBG (metaiodobenzylguanidine) or PET tracers like 18F-FDOPA—are transforming the localization and staging of pheochromocytoma. These modalities not only confirm tumor location and assess metastasis but also help differentiate between benign and malignant forms. Radioguided surgery and laparoscopic adrenalectomy have become standard in early-stage cases, offering minimally invasive alternatives with reduced recovery time and lower complication risks.

On the pharmacological front, pre-operative alpha-blockade using drugs like phenoxybenzamine or doxazosin remains standard to prevent intraoperative hypertensive crises. However, new treatment options are emerging for metastatic or inoperable pheochromocytoma, including tyrosine kinase inhibitors (TKIs), radiolabeled MIBG therapy, and combination chemotherapy regimens. Targeted molecular therapies and immuno-oncology approaches are under investigation, especially in genetically linked or recurrent cases, offering hope for long-term disease control.

Why Are Genetic Insights, Awareness Campaigns, and Registries Expanding Market Potential?

A major development shaping the pheochromocytoma landscape is the increasing use of next-generation sequencing (NGS) for risk stratification. Germline mutations in genes like RET, SDHB, and TMEM127 are being studied not only for diagnosis but also to predict prognosis and tailor treatment plans. Genetic counseling for at-risk family members is gaining importance in oncology and endocrinology clinics, opening doors for early intervention and preventive care.

Simultaneously, global efforts to build rare tumor registries and patient advocacy networks are improving research data availability, clinical trial participation, and pharmaceutical R&D investment. Awareness campaigns by organizations such as The Pheo Para Alliance and regional endocrine societies are improving diagnostic timelines and guiding standard-of-care practices. In turn, these efforts are expanding the addressable patient population and creating structured pathways for market growth in diagnostics, therapeutics, and follow-up care.

What’s Driving the Growth of the Global Pheochromocytoma Market?

The growth in the pheochromocytoma market is driven by several factors including improved diagnostic protocols, rising genetic screening rates, and the emergence of new treatment options for malignant and recurrent cases. A key growth driver is the convergence of multidisciplinary care—combining endocrinology, oncology, nuclear medicine, and genetics—which ensures more comprehensive and timely management.

Increased availability of imaging modalities, growth in rare disease funding, and patient advocacy initiatives are supporting earlier intervention and better outcomes. Furthermore, the introduction of advanced therapeutics for inoperable or metastatic cases—ranging from MIBG radiotherapy to kinase inhibitors—is adding commercial depth to what was previously a surgical-dominated market. As real-world evidence accumulates and clinical guidelines evolve, the pheochromocytoma market is positioned to expand gradually, especially within specialized oncology and endocrine care networks in North America, Europe, and parts of Asia-Pacific.

SCOPE OF STUDY:

The report analyzes the Pheochromocytoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Distribution Channel (Online Channel, Offline Channel); End-Use (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• ANI Pharmaceuticals, Inc.
• Apotex Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Baxter International Inc.
• Bristol-Myers Squibb Company
• Curium Pharma
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Endo International plc
• Exelixis, Inc.
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC
• Jubilant Cadista Pharmaceuticals Inc.
• Lantheus Holdings, Inc.
• Lupin Limited
• MediaPharma s.r.l.
• Merck & Co., Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.